PRESENTATION

Q3 2026 — Presentation

Q3 2026PDF · 28 pages2.2 MB
Third-Quarter 2026
Sales and Earnings
Merck & Co., Inc., Rahway, N.J., USA
October 29, 2026

-- 1 of 28 --

Agenda
2
Strategy and Business Update
Robert M. Davis
Chairman and Chief Executive Officer
Agenda
Financial Results and Outlook
Caroline Litchfield
Executive Vice President and Chief Financial Officer
Research Update
Dr. Dean Y. Li
Executive Vice President and President, Research Laboratories
Question & Answer Session

-- 2 of 28 --

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA
3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and
expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to
pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If
underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment; technological advances, new products and patents
attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign
risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future
events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements
can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

-- 3 of 28 --

Strategy and
Business Update
Robert M. Davis
Chairman and Chief Executive Officer
4

-- 4 of 28 --

¹Weber Shandwick/KCR Research, 2020 / AMO 2019 	5
$18.1B
Q3 Worldwide Sales
Increasing contributions from new products
Strength in Oncology and Animal Health
+5% nominal
+4% ex-exchange
1. In collaboration with Moderna
Achieved significant clinical and regulatory
progress, including:
Oncology
• 	Presented positive pivotal data at ESMO from multiple
novel candidates and broad oncology portfolio, including
sacituzumab tirumotecan and intismeran autogene1
Ophthalmology
• 	Presented results for remigromig from Phase 2b/3
BRUNELLO trial in DME at AAO
Immunology
• 	Presented results for tulisokibart from Phase 2b trial in HS
at EADV

-- 5 of 28 --

Successfully executing on strategy to broaden and diversify pipeline with
>20 current and future potential growth drivers
6	1. Future potential growth drivers reflect pipeline compounds currently being evaluated in Phase 2/3 or Phase 3 clinical trials. 2. In collaboration with Moderna 3. In collaboration with Gilead 4. In
collaboration with Daiichi Sankyo
1
2
3
Approved
islatravir / lenacapavir3
NRTI / capsid inhibitor
MK-1406
zanamivir-Fc conjugate
alimatravir
NRTI
islatravir + ulonivirine
NRTI + NNRTI
V181
Tetravalent dengue vaccine
Infectious Disease
Future potential growth drivers1
tulisokibart
TL1A mAb
Immunology
remigromig
Wnt agonist
MK-8748
Tie2 agonist/anti-VEGF
Ophthalmology
sacituzumab tirumotecan
TROP2 ADC
intismeran autogene2
INT
nemtabrutinib
BTK inhibitor
bomedemstat
LSD1 inhibitor
zilovertamab vedotin
ROR1 ADC
ifinatamab deruxtecan4
B7-H3 ADC
Oncology calderasib
KRAS G12C inhibitor
raludotatug deruxtecan4
CDH6 ADC
opevesostat
CYP11A1 inhibitor
patritumab deruxtecan4
HER3 ADC
MK-1045
CD19xCD3 T-cell engager
gocatamig3
DLL3 T-cell engager

-- 6 of 28 --

Financial Results
and Outlook
Caroline Litchfield
Executive Vice President and
Chief Financial Officer
7

-- 7 of 28 --

8
Q3 growth across human and animal health with increasing contributions
from new products
1. Worldwide Sales includes Other Revenue 2. Launch products include WINREVAIR, KEYTRUDA QLEX, CAPVAXIVE, OHTUVAYRE, ENFLONSIA, IDVYNSO, LIPFENDRA, BRAVECTO QUANTUM and
NUMELVI
$18.1B+5% nominal
+4% ex-exchange
WORLDWIDE SALES1
Human Health
$16.3B+4% growth
+4% ex-exchange
Animal Health
$1.7B+4% growth
+3% ex-exchange
3Q25 	3Q26
$2.2B
$0.8B
Launch product revenue2
OHTUVAYRE sales reported by Verona Pharma

-- 8 of 28 --

Oncology: KEYTRUDA continues to benefit patients and drive growth
9
KEYTRUDA family1 sales of $8.6B increased 6%
driven by strong uptake in earlier-stage cancers and
continued robust demand from metastatic
indications
‒ 	Growth driven by usage in tumors
predominantly affecting women, including those
with certain cervical and breast cancers
‒ 	Increased use in combination with Padcev
(enfortumab vedotin) in urothelial cancer and
continued uptake in earlier-stage head and neck
cancer
‒ 	U.S. YoY timing headwind largely offset by
increase in channel inventory, expected to
unwind in 4Q26
‒ 	KEYTRUDA QLEX sales of $830M in 3Q26
following launch in 3Q25 	3Q24 	3Q25 	3Q26
$7.4B
+21%2
$8.6B
+6%	$8.1B
+8%
Growth rates exclude the impact of foreign exchange 1. KEYTRUDA family includes KEYTRUDA and KEYTRUDA QLEX (available as KEYTRUDA SC in some markets) 2. ~3 percentage points of negative
impact of foreign exchange was due to devaluation of Argentine peso, which was largely offset by inflation-related price increases, consistent with practice in that market.

-- 9 of 28 --

3Q24 	3Q25 	3Q26
Oncology: Continued impact for patients across broad portfolio
10
WELIREG sales of $307M grew 58% driven by
continued higher demand in the U.S. and launch
uptake in international markets
Lynparza 1 alliance revenue of $352M decreased 7%
primarily due to lower net pricing in the U.S. and
lower demand and pricing in China
Lenvima 2 alliance revenue of $287M grew 11%
primarily due to higher demand in the U.S.
Growth rates exclude the impact of foreign exchange 1. In collaboration with AstraZeneca 2. In collaboration with Eisai
3Q24 	3Q25 	3Q26
$379M
+12%
$337M
+13%
$352M
-7%
3Q24 	3Q25 	3Q26
$258M
+2%
$251M
-4%
$287M
+11%
$139M
+157%
$196M
+41%
$307M
+58%

-- 10 of 28 --

3Q24 	3Q25 	3Q26
Vaccines & Infectious Diseases: Impacting lives globally
11
GARDASIL sales of $2.0B grew 14% driven by a
significant CDC purchase and higher price in the
U.S.
CAPVAXIVE1 sales of $263M grew 7% driven by
ongoing launches in certain international markets
and increased U.S. market share, partially offset by
lower pneumococcal vaccination rates in the U.S.
ENFLONSIA2 sales of $187M reflect seasonal
demand and inventory build
3Q24 	3Q25 	3Q26
$244M
N/M
$47M
$263M
+7%
3Q24 	3Q25 	3Q26
$79M$251M
-4%
$187M
+136%
$2.3B
-10% 	$1.7B
-25%
$2.0B
+14%
Growth rates exclude the impact of foreign exchange 1. Launched in 3Q24 2. Launched in 3Q25

-- 11 of 28 --

Cardiometabolic & Respiratory: Driving growth and continuing to benefit
patients with successful ongoing launches
WINREVAIR sales of $694M grew 94% driven by
continued growth in new patient starts and total
prescriptions, as well as a benefit from channel
inventory
‒ 	In the U.S., ~1,600 new patients prescribed and
>38,000 total prescriptions dispensed
‒ 	Ex-U.S., making progress with ongoing launches
OHTUVAYRE1 sales of $184M reflect continued
demand, partially offset by a small headwind from
timing of specialty pharmacy purchases
3Q24 	3Q25 	3Q26
$1.7B
+40%
3Q24 	3Q25 	3Q26
$184M
Growth rates exclude the impact of foreign exchange 1. Ohtuvayre was obtained as part of the acquisition of Verona Pharma on October 7, 2025 2. Sales reported by Verona Pharma
$360M
+141%
$694M
+94%
$135M2
$149M
12

-- 12 of 28 --

Animal Health: Solid growth driven by companion animal and livestock
13
Animal Health sales increased 3% to $1.7B
‒ 	Companion Animal sales grew 6% driven by new
product launches
‒ 	Livestock sales grew 2% driven by higher
demand for poultry products
3Q24 	3Q25 	3Q26
$1.5B
+11%1
$1.6B
+7%
$1.7B
+3%
Growth rates exclude the impact of foreign exchange 1. ~2 percentage points of negative impact of foreign exchange due to devaluation of Argentine peso, which was largely offset by inflation-related price
increases, consistent with practice in that market
Animal Health

-- 13 of 28 --

Q3 2026 non-GAAP financial results summary 1
$ in billions, except EPS amounts
14
1. The company is providing certain 2026 and 2025 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business
performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, annual employee
compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but not as a substitute for or
superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q3 2026 non-GAAP results include a charge of
$400 million, or $0.12 per share, related to an exclusive global license agreement with SciBrunch Therapeutics. Q3 2025 non-GAAP results include a $300 million charge, or $0.10 per share, related to the
LaNova Medicines technology transfer milestone payment. 3. Q3 2026 GAAP EPS of $2.04.
Q3 2026 	Q3 2025 	Change Change
Ex-FX
Sales 	$18.1 	$17.3 	+5% 	+4%
Non-GAAP Gross
Margin 81.4% 	81.9% 	-0.5pts 	-0.6 pts
Non-GAAP Operating
Expenses2 $7.4 	$6.6 	12% 	12%
Non-GAAP Tax Rate 	10.9% 	13.4% 	-2.5pts 	N/A
Non-GAAP EPS2,3 $2.49 	$2.58 	-3% 	-5%

-- 14 of 28 --

15
Updated 2026 financial outlook
1. Guidance does not assume additional significant potential business development transactions
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue 	$66.3B to $67.3B 	$66.8B to $67.3B • 	Assumes ~1 percentage point positive impact from FX
• 	Now implies +3% to +4% nominal (+2% to +3% ex-FX)
Non-GAAP
Gross Margin Rate ~81.0% 	~81.0%
Non-GAAP
Operating Expenses1 	$42.0B to $42.7B 	$42.4B to $42.9B • 	Now includes one-time $0.4B charge related to global
license agreement with SciBrunch Therapeutics
Other (Income) /
Expense ~$1.4B of expense 	~$1.4B of expense
Tax Rate 	~35.0% to 36.0% 	~32.0% to 33.0%
Shares Outstanding 	~2.48B 	~2.48B 	• 	Assumes ~$3B of share repurchases
Non-GAAP EPS1 	$2.66 to $2.76 	$2.77 to $2.82 • 	Incorporates $0.12 impact related to SciBrunch charge
• 	Assumes ~$0.15 positive impact from FX

-- 15 of 28 --

Key modeling considerations
16
U.S. Purchase Timing
• 	3Q26 benefitted from ~$550M of favorable
purchase timing
• 	Expect KEYTRUDA and WINREVAIR benefit to
fully unwind in 4Q26, and majority of vaccines
benefit, primarily GARDASIL, to unwind in 2027
KEYTRUDA
• 	Expect moderating growth as we approach peak
revenues for certain approved indications
• 	Expect German market to be impacted by policy
dynamics
BRIDION
• 	Experiencing competition from multiple generics
Operating Expense
• 	Anticipate underlying operating expenses to
increase mid- to high-single digits in 2027

-- 16 of 28 --

Remain committed to balanced capital allocation strategy
3Q Spend ($ in billions)1
17
1. Reflects quarter spend subject to finalization of the Company’s statement of cash flows 2. Reflects R&D excluding Business Development 3. Includes BD payments reflected in operating cash flow
Augmented our pipeline with
value-enhancing business
development while investing
in our pipeline and business
as well as returning cash to
shareholders
Capital allocation order of priority
$4.0
$1.0
$2.1
$0.7 	$0.7
After-Tax R&D² 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
3

-- 17 of 28 --

Research Update
Dr. Dean Y. Li
Executive Vice President and President,
Research Laboratories
18

-- 18 of 28 --

Meaningful progress across innovative oncology pipeline and portfolio
19
ESMO data highlights
• 	TroFuse-005: sac-TMT the first and only TROP2 ADC to
improve OS and PFS in certain patients with advanced
endometrial cancer1 versus chemotherapy2
− 	Reduced risk of death by 32%, extending median OS by
6.9 months (19.0 vs. 12.1)
− 	Reduced risk of disease progression or death by 41%
• 	OptiTROP-Lung063 : Positive findings from Phase 3 study
conducted in China evaluating sac-TMT plus KEYTRUDA
versus KEYTRUDA plus chemotherapy as 1L treatment for
patients with PD-L1-negative locally advanced or metastatic
non-squamous NSCLC
• 	INTerpath-001: intismeran autogene4 plus KEYTRUDA
improved RFS and DMFS over standard-of-care KEYTRUDA in
patients with completely resected stage IIB-IV melanoma
1. Advanced or recurrent endometrial cancer who have received prior platinum-based chemotherapy and anti-PD-1/L1 immunotherapy 2. Chemotherapy = treatment of physician’s choice (doxorubicin or
paclitaxel) 3. Conducted by Kelun Biotech 4. In collaboration
• 	Subcutaneous pembrolizumab and
berahyaluronidase alfa approved by
regulatory authorities in Japan and China
• 	EC approved KEYTRUDA plus Padcev as
perioperative treatment in adults with
resectable muscle-invasive bladder cancer
• 	FDA approved WELIREG plus LENVIMA for
treatment of patients with advanced ccRCC
following treatment with a PD-1/PD-L1
inhibitor
Recent regulatory milestones

-- 19 of 28 --

Expanding impact of WINREVAIR in pulmonary hypertension
20
WINREVAIR
• 	FDA approved update to U.S. label incorporating
positive results from Phase 3 HYPERION study in
adults on background therapy newly diagnosed1
with PAH at intermediate or high risk of disease
progression
• 	Plan to initiate Phase 3 CHORUS study in
patients with combined post- and pre-capillary
pulmonary hypertension associated with heart
failure with preserved ejection fraction shortly
Pulmonary hypertension development program
1. Diagnosed within 12 months
WHO Group 1
PAH
WHO Group 2
CpCPH-HFpEF
Phase 2
CADENCE
Phase 3
CHORUS

-- 20 of 28 --

Progressing late-stage immunology and ophthalmology pipeline
21
Tulisokibart
• 	Presented promising Phase 2b results in adults with
moderate to severe hidradenitis suppurativa, with
safety profile comparable to placebo
− 	First positive Phase 2 data for anti-TL1A antibody
in a dermatology indication
− 	Plan to advance to Phase 3 in HS
Remigromig
• 	Positive Phase 3 BRUNELLO presented at AAO
− 	Both doses (0.5mg and 0.8mg) of remigromig
independently demonstrated non-inferiority to
0.5mg ranibizumab in mean change from baseline
in BCVA at one year in adults with DME
• 	Potential first-in-class tetravalent tri-specific antibody
designed to agonize Wnt pathway to maintain vascular
integrity and reduce vascular leakage
• 	Anti-VEGF efficacy ceiling reached with up to 40% of
patients with persistent DME after six months of
treatment

-- 21 of 28 --

Significant late-stage pipeline milestones expected over next twelve
months
22
Cardiometabolic & respiratory
WINREVAIR
• 	Initiation of Phase 3 CHORUS study in CpcPH-
HFpEF
Efinopegdutide
• 	Presentation of results from Phase 2b trial in MASH
at AASLD
Immunology
Tulisokibart
• 	PCD in August for Phase 3 ATLAS-UC trial
• 	Phase 2 data in additional indications including RA,
R-axSpA and PsA
Ophthalmology
Remigromig
• 	PCD in March for Phase 2b/3 BAROLO trial in DME
1. In collaboration
Oncology
Sac-TMT
• 	PDUFA date June 15th based on TroFuse-005
• 	PCDs in January, May, and July for Phase 3 TroFuse program
Intismeran autogene1
• 	Anticipated regulatory filings
Infectious Disease
Efitazanamivir alfa (MK-1406)
• 	PCD in June for Phase 3 ANCHOR trial in prevention of influenza
Alimatravir
• 	PCD in July for Phase 3 EXPrESSIVE-11 trial in HIV PrEP
Islatravir/lenacapavir1
• 	Anticipated regulatory filings
IDVYNSO
• 	PDUFA date April 22nd based on MK-8591A-053 (treatment
naïve)
ENFLONSIA
• 	Second season SMART PDUFA date March 22 nd

-- 22 of 28 --

Q&A
Dr. Dean Y. Li
Executive Vice President
and President, Merck
Research Laboratories
Caroline Litchfield
Executive Vice President
and Chief Financial Officer
Robert M. Davis
Chairman and Chief
Executive Officer
Jannie Oosthuizen
Executive Vice President
and President, Oncology
and MSD International
Peter Dannenbaum
Senior Vice President,
Investor Relations
Brian Foard
Executive Vice President
and President, Specialty,
Pharma & Infectious
Diseases

-- 23 of 28 --

24
Appendix

-- 24 of 28 --

Q3 2026 GAAP financial results summary
$ in billions, except EPS amounts
25
Q3 2026 	Q3 2025 	Change 	Change Ex-FX
Sales 	$18.1 	$17.3 	+5% 	+4%
Operating Expenses
(SG&A and R&D)1,2 $7.4 	$6.9 	+8% 	+8%
Tax Rate 	8.9% 	14.2% 	-5.3 pts 	N/A
GAAP EPS1,2 $2.04 	$2.32 	-12% 	-13%
1. Q3 2026 GAAP results include a charge of $400 million, or $0.12 negative EPS impact, related to an exclusive global license agreement with SciBrunch Therapeutics. 2. Q3 2025 GAAP results include a
charge of $300 million, or $0.10 negative EPS impact, related to the LaNova Medicines technology transfer milestone payment

-- 25 of 28 --

2017 	2018 	2019 	2020 	2021 	2022 	2023 	2024 	2025 	2026
$13.8
$4.0
$8.4
$27.4
$3.5
$0
$5
$10
$15
$20
$25
$30
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
Billions
Capital allocation: Trailing twelve months
26
Capital allocation order of priority
3	2
Executing upon balanced capital allocation strategy
Over the past 12 months1
Committed to the dividend
+2% 	+2%
+15%
+11% +7% +6% +6%
+5%
+5%
+5%	Capital investments
2026 to 2030
~$19B
Over 5 years, including more than $14B in the U.S.
Well-positioned balance sheet with
capacity to fund additional value-
enhancing business development
opportunities
1. Reflects trailing twelve months spend subject to finalization of the Company’s statement of cash flows 2. Reflects R&D excluding Business Development 3. Includes BD payments reflected in operating cash
flow

-- 26 of 28 --

Broad and innovative pipeline to address significant unmet medical needs
27
As of November 4, 2026
Phase 3
Oncology
MK-1022 (patritumab
deruxtecan) 1
Breast
MK-1026 (nemtabrutinib)
Hematological Malignancies
MK-1084 (calderasib)
CRC
NSCLC
MK-2140 (zilovertamab
vedotin)
Hematological Malignancies
MK-2400 (ifinatamab
deruxtecan) 1
Esophageal
Prostate
SCLC
MK-2870 (sacituzumab
tirumotecan)
Bladder
Breast
Cervical
Endometrial (EU)
Gastric
NSCLC
Ovarian
MK-1406 (efitazanamivir alfa)
Influenza
LAGEVRIO (MK-4482) 1,3
COVID-19 (U.S.)
MK-8527 (alimatravir)
HIV-1 PrEP
MK-8591D (islatravir +
lenacapavir) 1,2
HIV-1 Infection
KEYTRUDA (MK-3475)
SCLC
MK-3543 (bomedemstat)
Myeloproliferative Disorders
MK-5684 (opevesostat)
Prostate
MK-5909 (raludotatug
deruxtecan) 1
Ovarian
LYNPARZA (MK-7339) 1
NSCLC
SCLC
V940 (intismeran autogene) 1
Melanoma
NSCLC
Infectious Diseases
MK-1022 (patritumab
deruxtecan) 1
Bladder
Cervical
Esophageal
Gastric
Melanoma
NSCLC
MK-1045
Hematological Malignancies
MK-1084 (calderasib)
Solid Tumors
MK-2010
Solid Tumors
MK-2400 (ifinatamab
deruxtecan) 1
Bladder
Endometrial
HCC
HNSCC
Melanoma
NSCLC
Ovarian
Solid Tumors
MK-2870 (sacituzumab
tirumotecan)
Biliary
Esophageal
Neoplasm Malignant
Oncology
Infectious Diseases
MK-8591B (islatravir +
ulonivirine)
HIV-1 Infection
MK-5884A (ensifentrine +
glycopyrrolate)
COPD
MK-6024 (efinopegdutide)
MASH
MK-7262
Atherosclerosis
WINREVAIR (MK-7962)
Pulmonary Hypertension due
to Left Heart Disease
Cardiometabolic &
Respiratory
MK-7240 (tulisokibart)
Axial Spondyloarthritis
Hidradenitis Suppurativa
Psoriatic Arthritis
Rheumatoid Arthritis
MK-8690
Ulcerative Colitis
Immunology
KEYTRUDA (MK-3475)
Prostate
KEYTRUDA QLEX (MK-3475A)
Hematological Malignancies
(U.S.)
MK-5684 (opevesostat)
Breast
Endometrial
Ovarian
MK-5909 (raludotatug
deruxtecan) 1
Cervical
Endometrial
Gastric
NSCLC
SCLC
MK-6070 (gocatamig) 1
SCLC
WELIREG (MK-6482)
Breast
V940 (intismeran autogene) 1
Bladder
RCC
MK-2214
Alzheimer’s Disease
Neuroscience
Under regulatory review
Oncology
MK-2870 (sacituzumab tirumotecan)
Previously Treated Endometrial (U.S.)
KEYTRUDA (MK-3475)
Cisplatin Eligible MIBC (JPN)
Cisplatin Ineligible MIBC (JPN)
Newly Diagnosed High-Risk Endometrial (EU)
WELIREG (MK-6482)
Clear Cell RCC Following Nephrectomy (EU,
JPN) 5
Previously Treated Advanced RCC (EU, JPN) 1,6
MK-7240 (tulisokibart)
Crohn’s Disease
Ulcerative Colitis
Immunology
MK-3000 (remigromig) 4
Diabetic Macular Edema
MK-8748 4
Neovascular Age-Related
Macular Degeneration
Ophthalmology
V181
Dengue Fever Virus
Vaccines
Phase 3	Phase 2
Infectious Diseases
IDVYNSO (MK-8591A)
HIV-1 Infection (EU)
HIV-1 Infection (Treatment Naïve) (US)
Cardiometabolic &
Respiratory
LIPFENDRA (MK-0616)
Hypercholesterolemia (EU, JPN)
1. Being developed in a collaboration 2. On FDA partial clinical hold for higher doses of islatravir than those used in current clinical trials 3. Available in the U.S. under Emergency Use Authorization, which will
terminate effective June 29, 2027 4. Program is in Phase 2/3 studies 5. Under review for combination use with KEYTRUDA 6. Under review in Japan for Lenvima, used in combination with WELIREG
ENFLONSIA MK-1654
Respiratory Syncytial Virus (2nd Season) (US,
EU, JPN)
Vaccines
OHTUVAYRE (MK-5884)
COPD (EU)
Cardiometabolic &
Respiratory

-- 27 of 28 --

28
AAO = American Academy of Ophthalmology
AASLD = American Association for the Study of Liver
Diseases
ADC = Antibody-drug conjugate
B7-H3 = B7 homolog 3
BCVA = Best corrected visual acuity
BTKi = Bruton Tyrosine Kinase inhibitor
ccRCC = Clear cell renal cell carcinoma
CDH6 = Cadherin-6
COPD = Chronic obstructive pulmonary disease
CpcPH-HFpEF = Combined postcapillary and
precapillary pulmonary hypertension associated with
heart failure with preserved ejection fraction
CRC = Colorectal cancer
CYP11A1 = Cytochrome P450 Family 11 Subfamily A
Member 1
DLL3 = Delta-like ligand 3
DME = Diabetic macular edema
DMFS = Distant metastasis-free survival
EADV = European Academy of Dermatology and
Venereology
ESMO = European Society for Medical Oncology
Acronyms
PCD = Primary completion date
PD-1/PD-L1 = Programmed cell death protein-
1/Programmed cell death ligand-1
PDUFA = Prescription Drug User Fee Act
PFS = Progression-free survival
PrEP = Pre-exposure prophylaxis
PsA = Psoriatic arthritis
RCC = Renal cell carcinoma
RA = Rheumatoid arthritis
R-axSpA = Radiographic axial spondyloarthritis
RFS = Recurrence-free survival
ROR1 = Receptor tyrosine kinase-like orphan receptor 1
SCLC = Small cell lung cancer
Tie2 = Tyrosine kinase with immunoglobulin-like and
EGF-like domains 2
TL1A = Tumor Necrosis Factor-like Ligand 1A
TROP2 = Trophoblast cell surface antigen-2
UC = Ulcerative colitis
VEGF = Vascular endothelial growth factor
Wnt = Wingless-related integration site Pathway
FZD4 = Frizzled-4
HCC = Hepatocellular carcinoma
HIV-1 = Human Immunodeficiency Virus Type 1
HNSCC = Head and neck squamous cell carcinoma
HS = Hidradenitis Suppurativa
INT = Individualized neoantigen therapy
KRAS = Kirsten rat sarcoma viral oncogene homolog
LRP5 = Low-Density Lipoprotein Receptor-Related
Protein 5
LSD1 = Lysine-specific demethylase 1
mAb = Monoclonal antibody
MASH = Metabolic Dysfunction-Associated
Steatohepatitis
MIBC = Muscle invasive bladder cancer
NRTI = Nucleoside reverse transcriptase inhibitor
NNRTI = Non-nucleoside reverse transcriptase
inhibitor
NSCLC = Non-small cell lung cancer
OS = Overall survival
PAH = Pulmonary arterial hypertension

-- 28 of 28 --